INDV · Insider Trading
Indivior Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by INDV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-27 | Woodrow D Anderson | Chief Accounting Officer | Buy | +1,500 | +$53.53K |
| 2026-08-05 | Woodrow D Anderson | Chief Accounting Officer | Buy | +1,500 | +$54.42K |
| 2026-07-13 | Christian Heidbreder | Chief Scientific Officer | Sell | −18,586 | −$764.63K |
| 2026-06-23 | Joseph Ciaffoni | Chief Executive Officer | MIXED | +654,354 | −$23.47M |
| 2026-06-12 | Christian Heidbreder | Chief Scientific Officer | Sell | −18,586 | −$707.38K |
| 2026-06-10 | Ryan Preblick | Chief Financial Officer | Sell | −36,000 | −$1.36M |
| 2026-05-14 | David E. Wheadon | Director | A | +10,430 | — |
| 2026-05-14 | Daniel A Ninivaggi | Director | A | +6,518 | — |
| 2026-05-14 | Barbara Ryan | Director | A | +6,518 | — |
| 2026-05-14 | Juliet Thompson | Director | MIXED | +5,401 | −$42.76K |
| 2026-05-14 | Mark Stejbach | Director | A | +6,518 | — |
| 2026-05-14 | Keith Humphreys | Director | A | +6,518 | — |
| 2026-05-14 | Stuart A Kingsley | Director | A | +6,518 | — |
| 2026-03-17 | Ryan Preblick | Chief Financial Officer | MIXED | +3,459 | −$88.45K |
| 2026-03-13 | Barbara Ryan | Director | Buy | +8 | +$249 |
| 2026-03-11 | Stuart A Kingsley | Director | Buy | +940 | +$29.95K |
| 2026-03-11 | Barbara Ryan | Director | Buy | +31 | +$1.01K |
| 2026-03-05 | Ryan Preblick | Chief Financial Officer | MIXED | −648 | −$2.80M |
| 2026-03-05 | Woodrow D Anderson | Chief Accounting Officer | MIXED | +13,345 | −$350.66K |
| 2026-03-05 | Jeffrey W Burris | Chief Legal Officer | MIXED | +43,861 | −$1.15M |
| 2026-03-05 | Christian Heidbreder | Chief Scientific Officer | MIXED | +55,747 | −$1.46M |
| 2026-02-12 | Patrick A Barry | Chief Commercial Officer | A | +31,380 | — |
| 2026-02-12 | Woodrow D Anderson | Chief Accounting Officer | A | +6,903 | — |
| 2026-02-12 | Christian Heidbreder | Chief Scientific Officer | A | +33,622 | — |
| 2026-02-12 | Ryan Preblick | Chief Financial Officer | A | +37,358 | — |
| 2026-02-12 | Joseph Ciaffoni | Chief Executive Officer | A | +79,976 | — |
| 2026-02-12 | Jeffrey W Burris | Chief Legal Officer | A | +26,897 | — |
| 2026-01-28 | Keith Humphreys | Director | A | +3,722 | — |
| 2026-01-28 | Stuart A Kingsley | Director | A | +3,722 | — |
| 2026-01-28 | Juliet Thompson | Director | A | +3,722 | — |
| 2026-01-28 | Barbara Ryan | Director | A | +3,722 | — |
| 2026-01-28 | Daniel A Ninivaggi | Director | A | +3,722 | — |
| 2026-01-28 | David E. Wheadon | Director | A | +5,955 | — |
| 2026-01-28 | Mark Stejbach | Director | A | +3,722 | — |
| 2026-01-07 | Barbara Ryan | Director | Buy | +775 | +$27.43K |
| 2026-01-07 | Daniel A Ninivaggi | Director | Buy | +775 | +$27.43K |
| 2026-01-07 | David E. Wheadon | Director | Buy | +1,771 | +$62.68K |
| 2026-01-07 | Keith Humphreys | Director | Buy | +775 | +$27.43K |
| 2026-01-07 | Mark Stejbach | Director | Buy | +775 | +$27.43K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joseph Ciaffoni | Chief Executive Officer | 790,330 | $28.67M |
| Ryan Preblick | Chief Financial Officer | 284,751 | $10.33M |
| Christian Heidbreder | Chief Scientific Officer | 209,337 | $7.59M |
| Jeffrey W Burris | Chief Legal Officer | 71,518 | $2.59M |
| Patrick A Barry | Chief Commercial Officer | 31,380 | $1.14M |
| David E. Wheadon | Director | 30,780 | $1.12M |
| Woodrow D Anderson | Chief Accounting Officer | 27,638 | $1.00M |
| Daniel A Ninivaggi | Director | 27,163 | $985.47K |
| Mark Stejbach | Director | 27,087 | $982.72K |
| Juliet Thompson | Director | 18,748 | $680.18K |
| Keith Humphreys | Director | 16,042 | $582.00K |
| Barbara Ryan | Director | 12,242 | $444.14K |
| Stuart A Kingsley | Director | 12,100 | $438.99K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INDV quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.